Shengtai Pharmaceutical Schedules 2009 Second Quarter Financial Results and Conference Call
February 12 2009 - 12:00PM
PR Newswire (US)
WEIFANG, Shandong, China, Feb. 12 /PRNewswire-Asia-FirstCall/ --
Shengtai Pharmaceutical, Inc. (OTC:SGTI) (BULLETIN BOARD: SGTI)
("Shengtai" or "the Company"), a leading manufacturer and
distributor of high-quality, pharmaceutical grade glucose products
in China, today announced that it will issue financial results for
the three months ended December 31, 2008 before the stock market
opens on Friday, February 13, 2009. Management will conduct a
conference call on Friday, February 13, 2009 at 9:00 A.M. Eastern
Standard Time to discuss these results. A question and answer
session will follow management's presentation. Mr. Qingtai Liu
(Chief Executive Officer), Ms. Yiru Melody Shi (Chief Financial
Officer), and Ms. Haining Michelle Wang (Investor Relations
Manager) will be the primary speakers on the call. A live webcast
of the conference call will be available by accessing the below
website at http://www.investorcalendar.com/IC/CEPage.asp?ID=141087
or on the Investor Relations page of Shengtai Pharmaceutical's web
site at http://www.shengtaipharmaceutical.com/ . Please visit the
Web site at least 15 minutes early to register for the webcast and
download any necessary audio software. To participate, please call
the following numbers ten minutes before the call start time: Phone
Number + 1 (877) 407-8035 (North America) Phone Number + 1 (201)
689-8035 (International) A replay of the call will be available
through Saturday, February 21, 2009, at 11:59 P.M. Eastern Standard
Time. For the replay, please call: Phone Number +1 (877) 660-6853
(North America) Phone Number +1 (201) 612-7415 (International)
Account Number: 286 Conference ID Number: 313673 About Shengtai
Pharmaceutical, Inc. Shengtai Pharmaceutical, Inc., through its
wholly owned subsidiary, Shengtai Holding, Inc. (SHI), and the
Chinese operating company of Weifang Shengtai Pharmaceutical Co.,
Ltd., is a leading manufacturer and supplier of pharmaceutical
grade glucose used for medical purposes. It also manufactures and
supplies glucose and cornstarch products to the food, beverage and
industrial production industries in China. For more information
about Shengtai Pharmaceutical, Inc., please visit
http://www.shengtaipharmaceutical.com/ . Safe Harbor Statement Safe
Harbor Statement under the Private Securities Litigation Reform Act
of 1995: Certain statements in this press release and oral
statements made by the Company constitute forward-looking
statements for purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995. These statements
include, without limitation, statements regarding our ability to
prepare the Company for growth, the Company's planned capacity
expansion and predictions and guidance relating to the Company's
future financial performance. We have based these forward-looking
statements largely on our current expectations and projections
about future events and financial trends that we believe may affect
our financial condition, results of operations, business strategy
and financial needs, but they involve risks and uncertainties that
could cause actual results to differ materially from those in the
forward-looking statements, which may include, but are not limited
to, such factors as unanticipated changes in product demand
especially in the pharmaceutical industry, pricing and demand
trends for the Company's products, changes to government
regulations, risk associated with operation of the Company's new
facilities, risk associated with large-scale implementation of the
Company's business plan, the ability to attract new customers,
ability to increase its product's applications, cost of raw
materials, downturns in the Chinese economy, and other information
detailed from time to time in the Company's filings and future
filings with the United States Securities and Exchange Commission.
Investors are urged to consider these factors carefully in
evaluating the forward-looking statements herein and are cautioned
not to place undue reliance on such forward-looking statements,
which are qualified in their entirety by this cautionary statement.
The forward-looking statements made herein speak only as of the
date of this press release and the Company undertakes no duty to
update any forward-looking statement to conform the statement to
actual results or changes in the Company's expectations. For more
information, please contact: Shengtai Pharmaceutical, Inc. Ms. Yiru
Melody Shi Chief Financial Officer Email: Grayling Eddie Cheung
Investor Relations Tel: +1-646-284-9414 Email: DATASOURCE: Shengtai
Pharmaceutical, Inc. CONTACT: Ms. Yiru Melody Shi, Chief Financial
Officer, Shengtai Pharmaceutical, Inc. at ; or Eddie Cheung,
Investor Relations, Grayling at +1-646-284-9414 or Web site:
http://www.shengtaipharmaceutical.com/
http://www.investorcalendar.com/IC/CEPage.asp?ID=141087
Copyright